Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Overcoming endocrine resistance in breast cancer.
Madaio RA, Spalletta G, Cravello L, Ceci M, Repetto L, Naso G. Madaio RA, et al. Among authors: naso g. Curr Cancer Drug Targets. 2010 Aug;10(5):519-28. doi: 10.2174/156800910791517226. Curr Cancer Drug Targets. 2010. PMID: 20384578 Review.
Circulating tumor cells in cancer therapy: are we off target?
Raimondi C, Naso G, Gradilone A, Gianni W, Cortesi E, Gazzaniga P. Raimondi C, et al. Among authors: naso g. Curr Cancer Drug Targets. 2010 Aug;10(5):509-18. doi: 10.2174/156800910791517163. Curr Cancer Drug Targets. 2010. PMID: 20384574 Review.
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.
Frassoldati A, Biganzoli L, Bordonaro R, Cinieri S, Conte P, Laurentis M, Mastro LD, Gori S, Lauria R, Marchetti P, Michelotti A, Montemurro F, Naso G, Pronzato P, Puglisi F, Tondini CA. Frassoldati A, et al. Among authors: naso g. Future Oncol. 2020 Feb;16(5):129-145. doi: 10.2217/fon-2018-0942. Epub 2019 Dec 18. Future Oncol. 2020. PMID: 31849236 Review.
Circulating tumor cells count and characterization in a male breast cancer patient.
Gazzaniga P, Naso G, Raimondi C, Gradilone A, Palazzo A, Gandini O, Petracca A, Nicolazzo C, Cortesi E, Frati L. Gazzaniga P, et al. Among authors: naso g. Cancer Biol Ther. 2011 Sep 1;12(5):379-82. doi: 10.4161/cbt.12.5.16304. Epub 2011 Sep 1. Cancer Biol Ther. 2011. PMID: 21725206 Free article.
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L; Gruppo Italiano Mammella (GIM) study group. Conte B, et al. Among authors: naso g. Clin Breast Cancer. 2020 Apr;20(2):e181-e187. doi: 10.1016/j.clbc.2019.09.001. Epub 2019 Nov 14. Clin Breast Cancer. 2020. PMID: 31735691
Pancreatic cancer: from molecular signature to target therapy.
Longo R, Cacciamani F, Naso G, Gasparini G. Longo R, et al. Among authors: naso g. Crit Rev Oncol Hematol. 2008 Dec;68(3):197-211. doi: 10.1016/j.critrevonc.2008.03.003. Epub 2008 Apr 23. Crit Rev Oncol Hematol. 2008. PMID: 18436450 Review.
56 results